甲磺酸去铁胺联合去铁酮治疗重型β地中海贫血铁过载患儿的效果  

The Effect of Desferrioxamine Mesilate Combined with Deferiprone in the Treatment of Children with Severe β Thalassemia Iron Overload

作　　者：陈书远[1] 刘金宝[1] 刘世祺 CHEN Shuyuan;LIU Jinbao;LIU Shiqi(First People’s Hospital of Huizhou,Huizhou 516001,China;不详)

机构地区：[1]惠州市第一人民医院,广东惠州516001

出　　处：《中外医学研究》2022年第5期62-65,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨甲磺酸去铁胺联合去铁酮治疗重型β地中海贫血铁过载患儿的效果。方法:选取2018年9月1日-2019年8月31日惠州市第一人民医院收治的60例重型β地中海贫血铁过载患儿,采用掷硬币法分为对照组(31例)和观察组(29例)。对照组给予去铁酮治疗,观察组给予甲磺酸去铁胺联合去铁酮治疗。比较两组疗效、治疗期间尿铁排泄量(UIE)、治疗前后心脏和肝脏MRI T_(2)^(*)值及不良反应发生情况。结果:观察组总有效率为82.76%,高于对照组的54.84%,差异有统计学意义(P<0.05)。治疗6、12个月,观察组UIE均高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组心脏和肝脏的MRI T_(2)^(*)值均高于治疗前,且观察组均高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:甲磺酸去铁胺联合去铁酮治疗重型β地中海贫血患儿可提高临床效果,促进铁清除、降低铁过载对心脏和肝脏的影响,且不增加不良反应发生率。Objective:To investigate the effect of Desferrioxamine Mesilate combined with Deferiprone in the treatment of children with severeβthalassemia iron overload.Method:A total of 60 children with severeβthalassemia with iron overload admitted to the First People’s Hospital of Huizhou from September 1,2018 to August 31,2019 were selected,they were divided into control group(31 cases)and observation group(29 cases)according to toss coin.The control group was treated with Deferiprone,and the observation group was treated with Desferrioxamine Mesilate combined with Deferiprone.The efficacy,urinary iron excretion(UIE)during treatment,MRI T_(2)^(*) values of heart and liver before and after treatment and the incidence of adverse reactions were compared between two groups.Result:The total effective rate of the observation group was 82.76%,which was higher than 54.84%of the control group,the difference was statistically significant(P<0.05).After 6 and 12 months of treatment,UIE of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).After treatment,MRI T_(2)^(*) values of heart and liver were higher than those before treatment,and those of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Desferrioxamine Mesilate combined with Deferiprone in the treatment of severeβthalassemia can improve the clinical efficacy,promote iron clearance,reduce the impact of iron overload on the heart and liver,and does not increase the incidence of adverse reactions.

关 键 词：甲磺酸去铁胺 去铁酮 重型Β地中海贫血 铁过载 

分 类 号：R725.5[医药卫生—儿科]